Alamar Biosciences reported total revenue of $33.5 million for the third quarter of 2026, representing a 68% year-over-year increase and exceeding analyst estimates. The growth was supported by the increasing adoption of the NULISA platform, particularly among biopharma customers who now constitute the company's largest revenue segment.
Key Highlights
- Consumable revenue surged 79% YoY to $17.8 million, maintaining its position as the largest revenue driver at 53% of the total mix.
- Instrument revenue grew 50% to $8.5 million, reflecting continued expansion of the ARGO HT system install base.
- Gross margin expanded to 61.5% from 59.7% in the prior year, aided by lower instrument costs and higher consumable pricing.
- Full-year 2026 revenue guidance was raised to a range of $121 million to $123 million, up from the previous $116 million to $120 million.
- The company secured major large-scale profiling studies with the UK Biobank (80,000 samples) and GSK (60,000 samples).